

Joint Cooperation Agreements with PolyPeptide Group and Recipharm AB in anticipation of clinical trials

As previously announced, Follicum estimates it will be ready for the commencement of clinical trials around the beginning of 2016. The company is pleased to announce two cooperative partners – the PolyPeptide Group and Recipharm AB – in anticipation of the clinical trials.

In early May 2015, Follicum announced the company had a successful scientific advisory meeting with the German pharmaceutical regulatory authority, Federal Institute for Drugs and Medical Devices (BfArM), and that the company's clinical trials are planned to be implemented in Germany. The preparations for the clinical trials, which are scheduled to commence the beginning of 2016 or shortly before, are underway and Follicum has established relationships with two joint cooperation partners who produce the products that will be used in the clinical trials. The PolyPeptide Group manufactures Follicum's peptide and Recipharm AB's remit includes formulating and producing the product that will be used in the clinical trials. The assignment includes developing and validating the analytical methods that are required. The process has begun and the product is expected to be completed by the end of the year.

Jan Alenfall, CEO Follicum, comments

- Preparations for the clinical trials are well underway and we have now established relationships with two cooperative partners that we are confident about. Both of these two companies are very successful in their fields and have solid records of accomplishment. We expect the finished product being ready by the end of the year, for the commencement of the clinical trials.

Jan Christensen, Global Sales Director PolyPeptide, comments

- This product fits well within our portfolio, through our comprehensive manufacturing and support services. PolyPeptide assists innovative companies with their peptide development needs.

Maria Lundberg, CEO Recipharm, comments

- We have extensive experience in the development of pharmaceuticals for clinical trials and are very excited to be able to contribute to the development of this product.

PolyPeptide Group in brief

The PolyPeptide Group produces peptides and peptide-related molecules for Biotech and Pharmaceutical companies on a contract or custom basis. The company currently employs more than 470 employees, primarily highly educated and experienced peptide chemists in six production plants in France, India, Denmark, Sweden and the United States. The PolyPeptide Group is considered – in terms of sales of peptide-based drugs for the human and veterinary markets – as a world-leading manufacturer of pharmaceutical grade peptides. The company was founded in Malmö, Sweden.

Recipharm AB in brief

Recipharm AB offers manufacturing services for pharmaceutical medicines in different formulations, production of clinical trial material including the active drug, and pharmaceutical product development. The company has approximately 2,200 employees and manufactures over 400 different products for customers ranging from Big Pharma to small research and development companies. Recipharm AB conducts its research & development and production in Sweden, France, UK, Germany, Spain, Italy and Portugal, and is headquartered in Jordbro, Sweden.

For further information, please contact:

Jan Alenfall – CEO, Follicum AB
Telephone: +46 (0)46 - 19 21 97
E-mail: info@follicum.com

About Follicum AB

Follicum focuses on the development of the pharmaceutical candidate FOL-005 which in preclinical studies has both stimulated and inhibited hair growth effectively even at low doses. The Company's objective is to generate returns and revenues for other future projects by means of a sale or outlicensing of FOL-005 after a successful phase I/IIa trial.